Mr Eric Low,
Chief Executive
Myeloma UK

Eric established Myeloma UK twelve years ago after volunteering in the United States for the International Myeloma Foundation and realising there was a need for an organisation to provide information and support to people affected by myeloma in the UK. Since then Myeloma UK has grown and flourished due to Eric�s limitless commitment and enthusiasm. It now provides a broad and innovative range of services, covering every aspect of myeloma, from information and support, to improving standards of treatment and care through education, research, campaigning and raising awareness. The organisation reaches over 12,000 people affected by myeloma and is staffed by a small but effective team, managed by a Board of Directors and guided by expert advisory boards. As Chief Executive, Eric has been instrumental in developing the organisation�s �bench to bedside� strategy, which stands as an optimal integrated model and is the only one of its kind in the UK. Amongst a very busy portfolio of projects Eric�s principle focus at the moment is in establishing a national early phase trial network and a myeloma genetics and drug development research programme. Eric also spends much of his time out and about meeting with representatives from the myeloma community, tirelessly advocating and campaigning on behalf of myeloma patients for the very best standards of treatment and care. Through his passion and enthusiasm he has significantly raised the profile of myeloma in the medical, political and media arena.

Appearing:

Day Two - Thursday 10 December 2009

12pm

Patient involvement in HTA

This panel discussion will provide an insight into current and future patient involvement and influence in technology assessment appraisals.

brian@vhcltd.co.uk Brian Lovatt,
(Moderator)

Chief Executive Officer,
Vision Healthcare Consultancy

Alastair Kent,
(Confirmed)

Director,
Genetic Interest Group

Mr Eric Low,
(Confirmed)

Chief Executive,
Myeloma UK

back to programme »

view all speakers »

Sponsors

our speakers

Meindert Boysen

Associate Director Single Technology Appraisals

NICE

Dr François Meyer

Director, Health Technology Assessment Division

Haute Autorité de

Santé

Dr Allan Korn

Senior Vice President, Chief Medical Officer

BlueCross BlueShield Association

Jerome Boehm

Head EU level activities on HTA

European Commission

Dr Matthias Perleth

Head of Methods Department

Gemeinsamer Bundesausschuss

Mr Eric Low,Chief ExecutiveMyeloma UK

Patient involvement in HTA

Mr Eric Low,
Chief Executive
Myeloma UK